hVIVO, a subsidiary of Dublin-listed Open Orphan has won a $13.4 million (€11.8 million) contract with a leading US biotech company.
The contract will see the unnamed company testing its novel antiviral candidate using the Hvivo influenza human challenge study model.
The study is expected to commence in the first half of 2022 and will be conducted at Hvivo’s quarantine facilities in London. The company expect the majority of revenues arising from the deal to be recognised next year.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).